Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Income from Continuing Operations (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Income from Continuing Operations for 7 consecutive years, with 20334000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 22.73% to 20334000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 74880000.0, a 21.51% increase, with the full-year FY2025 number at 74880000.0, down 669.97% from a year prior.
  • Income from Continuing Operations was 20334000.0 for Q4 2025 at Fulcrum Therapeutics, down from 19595000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 16568000.0 in Q4 2024 to a low of 34070000.0 in Q2 2022.
  • A 5-year average of 22222857.14 and a median of 20525000.0 in 2021 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 73.4% in 2022, then surged 34.29% in 2025.
  • Fulcrum Therapeutics' Income from Continuing Operations stood at 23484000.0 in 2021, then crashed by 45.08% to 34070000.0 in 2022, then rose by 29.51% to 24017000.0 in 2023, then skyrocketed by 31.02% to 16568000.0 in 2024, then dropped by 22.73% to 20334000.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Income from Continuing Operations are 20334000.0 (Q4 2025), 19595000.0 (Q3 2025), and 17296000.0 (Q2 2025).